Potencies and efficacies of compounds evaluated in PI turnover assay in A7r5 cells
| Compound | Potency (EC50, nM)a,b | Efficacy (Emax, %) |
|---|---|---|
| Cloprostenol | 0.84 ± 0.06 (34) | 100 |
| 16-Phenoxy PGF2α | 2.05 ± 0.19 (4) | 88.8 |
| 17-Phenyl PGF2α | 2.80 ± 0.59 (4) | 84.3 |
| Fluprostenol | 4.45 ± 0.19 (19) | 100 |
| PGF2α | 30.9 ± 2.82 (7) [8.0]* | 86.4 |
| PhXA85 | 43.5 ± 11.4 (4) [10.0]* | 85.2 |
| PGD2 | 222.0 ± 71.4 (7) [100]* | 50.9 |
| 11-Deoxy PGF2α | 291.0 ± 21.3 (4) | 68.8 |
| Enprostil | 317.3 ± 78.9 (3) | 83.2 |
| 17-Phenyl PGE2 | 429.0 ± 107 (4) | 69.6 |
| PGE2 | 2607 ± 270 (3) [500]* | 63.1 |
| Sulprostone | 3410 ± 860 (4) | 61.2 |
| U-46619 | 5900 ± 1230 (5) | 63.4 |
| Iloprost | Inactive | |
| 8-Isoprostane | Inactive | |
| Arg8-vasopressin | 2.69 ± 0.33 (16) | 62.1 |
| Bombesin | 4.27 ± 0.36 (4) | 60.5 |
| Serotonin | 121 ± 10.7 (3) | 26.5 |
| Angiotensin II | Inactive | |
| Bradykinin | Inactive | |
| Histamine | Inactive | |
| Carbachol | Inactive |
1-a Data are mean ± S.E.M., for n = 3 to 34 experiments, as indicated in parentheses, with triplicate determinations in each experiment. Efficacy (Emax) was computed relative to the maximal response produced by cloprostenol, included as the “standard” agonist in each experiment. The S.E.M. in Emax values was ≤10%.
1-b The potency values designated by square brackets * are estimates from data of Goh and Kishino, 1994, for the contractile response of isolated cat iris sphincter muscle.